Literature DB >> 9722300

Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group.

J Donadieu1, M F Auclerc, A Baruchel, T Leblanc, J Landman-Parker, Y Perel, G Michel, G Cornu, P Bordigoni, D Sommelet, G Leverger, C Hill, G Schaison.   

Abstract

We determined the proportion of survival variability explained by the usual prognostic factors in childhood acute lymphoblastic leukaemia (ALL) during a prognostic study of 1552 patients enrolled in three consecutive Fralle group protocols (Fralle 83, Fralle 87 and Fralle 89). The event-free survival rates at 5 years were 54.8% (SD 1.9), 43.1%) (SD 2.7) and 55.6% (SD 2.2), respectively. In the univariate analysis the following variables were predictive of poor outcome: male gender, elevated leucocytosis (> 50 x 10(9)/l), circulating blastosis. haemoglobin >12 g/dl, platelet count <100 x 10(9)/l, age under 1 year or over 9 years, enlarged mediastinum, nodes, spleen and liver, T phenotype, absence of CD10+ cells; testicular and meningeal involvement, poor response to induction therapy (CCSG M3), and LDH >400 U/l. Among the cytogenetic features, hyperdiploidy had a protective effect, whereas hypodiploidy, translocation and other structural abnormalities had a negative influence, particularly in cases of t(9;22) or t(4;11). Multivariate analysis summarized the prognostic information in terms of four variables: age, gender, leucocytosis and cytogenetic features. Missing data had little influence on the results. However, despite their significance in the multivariate analysis, these four variables each had very low predictive power (1.1% for gender, 2.0% for age, 3.5% for leucocytosis, and 1.6% for cytogenetic features). Thus, the most significant prognostic factors in childhood ALL each explain no more than 4% of the variability in prognosis. This may explain the disappointing practical value of these factors and underlines the need for prognostic tools in childhood ALL.

Entities:  

Mesh:

Year:  1998        PMID: 9722300     DOI: 10.1046/j.1365-2141.1998.00818.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.

Authors:  Lesley Mitchell; Moritz Lambers; Silke Flege; Gili Kenet; Valerie Li-Thiao-Te; Susanne Holzhauer; Christoph Bidlingmaier; Michael C Frühwald; Christine Heller; Wolfgang Schmidt; Brigitte Pautard; Ulrike Nowak-Göttl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

2.  Adult T Lymphoblastic Leukemia (Pro-T ALL) with Reactive Monocytosis: A Case Report.

Authors:  Rachna Khera; Parul Gautam; Sanjeev Gupta; Prerna Arora; Tejinder Singh; Naresh Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-21       Impact factor: 0.900

Review 3.  Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining.

Authors:  Paul S Gaynon
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

4.  Prognostic value of early response to treatment combined with conventional risk factors in pediatric acute lymphoblastic leukemia.

Authors:  Akira Morimoto; Kikuko Kuriyama; Shigeyoshi Hibi; Shinjiro Todo; Takao Yoshihara; Hiroshi Kuroda; Shibsaku Imashuku
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 5.  Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors:  Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study.

Authors:  C Oudin; P Auquier; Y Bertrand; A Contet; J Kanold; N Sirvent; S Thouvenin; M-D Tabone; P Lutz; S Ducassou; D Plantaz; J-H Dalle; V Gandemer; S Beliard; J Berbis; C Vercasson; V Barlogis; A Baruchel; G Leverger; G Michel
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

7.  Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia.

Authors:  G S Nouman; J J Anderson; K M Wood; J Lunec; A G Hall; M M Reid; B Angus
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

8.  Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment.

Authors:  Susan Kim; Moussa El-Hallak; Fatma Dedeoglu; David Zurakowski; Robert C Fuhlbrigge; Robert P Sundel
Journal:  Arthritis Rheum       Date:  2009-06

Review 9.  Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use.

Authors:  Joël Schlatter; David Nguyen; Michèle Zamy; Sofiane Kabiche; Jean-Eudes Fontan; Salvatore Cisternino
Journal:  Eur Spine J       Date:  2017-11-18       Impact factor: 3.134

10.  MR imaging of the brain in patients cured of acute lymphoblastic leukemia--the value of gradient echo imaging.

Authors:  M S M Chan; D J Roebuck; M-P Yuen; C-K Li; Y-L Chan
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.